Latest filings (excl ownership)
8-K
Regulation FD Disclosure
18 Apr 24
DEFA14A
Additional proxy soliciting materials
16 Apr 24
ARS
2023 FY
Annual report to shareholders
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
10-K
2023 FY
Annual report
12 Feb 24
8-K
Results of Operations and Financial Condition
31 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
8 Nov 23
8-K
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
4 Oct 23
8-K
Teva Announces Changes to Executive Management Team
28 Sep 23
8-K
Entry into a Material Definitive Agreement
24 Aug 23
8-K
Departure of Directors or Certain Officers
2 Aug 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Results of Operations and Financial Condition
2 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Teva Concludes Nationwide Opioids Settlement Agreement
8 Jun 23
DEFA14A
Additional proxy soliciting materials
24 May 23
SD
Conflict minerals disclosure
24 May 23
8-K
Departure of Directors or Certain Officers
11 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Results of Operations and Financial Condition
10 May 23
ARS
2022 FY
Annual report to shareholders
19 Apr 23
DEFA14A
Additional proxy soliciting materials
19 Apr 23
DEF 14A
Definitive proxy
19 Apr 23
8-K
Entry into a Material Definitive Agreement
9 Mar 23
8-K
Regulation FD Disclosure
3 Mar 23
424B5
Prospectus supplement for primary offering
3 Mar 23
FWP
Free writing prospectus
1 Mar 23
424B5
Prospectus supplement for primary offering
27 Feb 23
10-K
2022 FY
Annual report
10 Feb 23
F-6EF
Automatic registration for ADRs (foreign)
8 Feb 23
8-K
Results of Operations and Financial Condition
8 Feb 23
UPLOAD
Letter from SEC
21 Dec 22
CORRESP
Correspondence with SEC
20 Dec 22
UPLOAD
Letter from SEC
1 Dec 22
8-K
Teva Announces Appointment of Richard Francis as President and CEO
21 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Key financial highlights and outlook
3 Nov 22
CORRESP
Correspondence with SEC
26 Oct 22
UPLOAD
Letter from SEC
13 Sep 22
Latest ownership filings
SC 13G/A
Phoenix Holdings Ltd.
9 Apr 24
4
Eliyahu Sharon Kalif
7 Mar 24
4
Eric Drape
7 Mar 24
4
Richard Daniell
7 Mar 24
4
Vikki L Conway
7 Mar 24
4
Mark Sabag
7 Mar 24
4
Amir Weiss
7 Mar 24
4
David R. McAvoy
5 Mar 24
3
David R. McAvoy
5 Mar 24
4
Vikki L Conway
5 Mar 24
4
Christine Fox
5 Mar 24
4
Angus Grant
5 Mar 24
4
Richard D Francis
5 Mar 24
4
Eric Drape
5 Mar 24
4
Richard Daniell
5 Mar 24
4
Eric A Hughes
5 Mar 24
4
Mark Sabag
5 Mar 24
4
Eliyahu Sharon Kalif
5 Mar 24
4
Amir Weiss
5 Mar 24
4
Dov Bergwerk
1 Mar 24
4
Eliyahu Sharon Kalif
1 Mar 24
4
Mark Sabag
1 Mar 24
4
Amir Weiss
1 Mar 24
4
Eric Drape
1 Mar 24
4
Richard Daniell
1 Mar 24
4
Vikki L Conway
1 Mar 24
4
Eric Drape
21 Feb 24
4
Richard D Francis
20 Feb 24
4
Eliyahu Sharon Kalif
15 Feb 24
4
Amir Weiss
5 Feb 24
SC 13G
Phoenix Holdings Ltd.
1 Feb 24
4
Richard Daniell
1 Feb 24
4
Eliyahu Sharon Kalif
1 Feb 24
4
Eric Drape
1 Feb 24
4
Mark Sabag
1 Feb 24
4
Christine Fox
22 Nov 23
3
Christine Fox
22 Nov 23
4
Vikki L Conway
16 Nov 23
4
Dov Bergwerk
16 Nov 23
3
Dov Bergwerk
18 Oct 23